Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

CNS Drug Discoveries: Depression Chapter

Published by: Espicom Healthcare Intelligence

Published: Nov. 27, 2006 - 92 Pages


Table of Contents


DEPRESSION

EXECUTIVE SUMMARY

THE FACTS


What is depression and why are we interested in it?


PATIENT STATISTICS


Incidence, diagnosis rates and treatment; now and in the future


PATIENT MODEL



Summary of patient population forecasts in seven major markets (2005A-2012E)


Model assumptions


DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

GLOBAL ANTIDEPRESSANT MARKET


Global CNS Market (US$687 billion)


GLOBAL SALES SPLIT



Global sales by region (2005A)


US market


Antidepressant US drugs sales by (2005A)


European market


European Antidepressant sales by (2005A)


ROW/Japanese market

The Major Players Products in 2005 & 2006


Market share of Antidepressant players by sales (Dec 2005A)


The Major Players and Products in 2012


Market share of Antidepressant Players by sales (Dec 2012E)



CURRENT TREATMENTS


Leading Brands


Comparison of leading antidepressant drugs


Patent Exposure of Current Products


Patent Exposure of Leading Antidepressant Brands



ANALYSIS OF LEADING BRANDS

Selective Serotonin Reuptake Inhibitors (SSRIs)


Lexapro/Cipralex (Forest/Lundbeck)

Prozac (Eli Lilly)

Zoloft (Pfizer)


Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)


Cymbalta (Eli Lilly)

Effexor (Wyeth)


Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)


Wellbutrin (GlaxoSmithKline)


GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012


Sales Forecasts of Current Leading Antidepressant Drugs

Model assumptions


NEW DRUGS IN R&D


Drugs in Development to Treat Depression and Anxiety Related Disorders


ANALYSIS OF PHASE III DRUGS



New Drugs in Phase III Development to Treat Depression and Anxiety


Phase III drugs

Other Phase III drugs of interest


Triple Reuptake Inhibitors (TRIs)


DOV216,303(Merck&Co/DOVPharmaceuticals)


Potency of Antidepressants on Amine Reuptake (nanomoles)



Serotonin Noradrenaline Reuptake Inhibitor (SNRI)


Pristiq(Wyeth)


Neurokinin (NK) Receptor Antagonist


Saredutant(sanofi-aventis)

Vilazodone(ClinicalData)


GLOBAL SALES FORECASTS OF PHASE III ANTIDEPRESSANT AND ANTI-ANXIETY DRUGS 2006 - 2012



Sales Forecasts of Phase III Developmental Drugs for Depression and Anxiety


Model assumptions


ANALYSIS OF PHASE II DRUGS



New Drugs in Early Clinical Development to Treat Depression and Anxiety


NS2359(NeuroSearch/GlaxoSmithKline)



NK Receptor Antagonists


Vestipitant+Paroxetine(GlaxoSmithKline)

Nemifitide(TetragenexPharmaceuticals)



GLOBAL SALES FORECASTS OF PHASE II ANTIDEPRESSANT DRUGS 2006 - 2012



Sales Forecasts of Phase II Developmental Antidepressant Drugs


Model assumptions


COMPETITOR RATIO ANALYSIS - PRODUCTS


CR Analysis of Antidepressant Agents Approved by 2012 - Based on Drug Class


COMPETITOR RATIO ANALYSIS - COMPANIES



CR Analysis of Antidepressant Agents Approved by 2012 - Based on Company


WINNERS & LOSERS


Summary of Key Companies and Drugs in the Antidepressant Market by 2012

Winners

Losers


DISCONTINUATION OF DRUGS


Antidepressants/Anxiolytics discontinued from clinical development


DEPRESSION APPENDIX 1


Assessment of Depression Criteria


DEPRESSION APPENDIX 2


Phasetransition probability

Probability of launch


DEPRESSION APPENDIX 3


Patient Model


Summary of US Depression and Anxiety Patient Population Forecasts

Summary of Europe (Top 5) Depression and Anxiety Patient Population Forecasts

Summary of Japanese Depression and Anxiety Patient Population Forecasts



DEPRESSION APPENDIX 4


Global Antidepressant Drugs Sales 2005A-20012E


DEPRESSION APPENDIX 5


Competitor Ratio Analysis Criteria


Key Antidepressant/Anxiolytic Drugs on the Market by 2012



DEPRESSION GLOSSARY

DEPRESSION REFERENCES

ACRONYMS

Abstract

The market for antidepressive drugs is the largest segment of the CNS sector with global sales of US$16.2 billion in 2005. Find out more in this chapter of CNS Drug Discoveries.

The market for antidepressive drugs is the largest segment of the CNS sector with global sales of US$16.2 billion in 2005, and annual growth of 2% year on year. This is a saturated market where a number of generics have been launched and eroded the market share of leading brands. This chapter focuses on the ways in which companies have optimised the life-cycle of their products through new formulations, combination and new products in order to protect their franchises. It looks at the changing dynamics in the marketplace and evaluates how effective the launch of Cymbalta (Eli Lilly), and Wellbutrin XL (GSK), have been.

It is estimated that depression affects over 18.8 million US citizens and over 121 million people worldwide, with approximately 20% of the global population at risk of developing major depression at some point in their lives. Women are almost twice as likely to suffer from depression as men (9.5% versus 5.8%), but prevalence figures vary from country to country. Depression costs the US economy an estimated US$44 billion each year and the WHO predicts depression will become the leading cause of disability by the year 2020.

Global depression market

The global market for antidepressants is unevenly distributed. In 2005, the US antidepressant market accounted for 66% of the global market compared to 23% in Europe and 11% rest of world (largely Japan).

We believe the depression market is now saturated as numerous formulations, combinations and generics are available. In order for new products to capitalise on this market they will have to demonstrate improvements in the efficacy, speed of onset, safety/tolerability of drugs and a reduction in remission rates and relapse/recurrence.

Key questions answered in this chapter include:
  • What impact have generics had on GSK and Lundbeck/Forest’s antidepressant franchise?
  • To what degree have Cymbalta (Eli Lilly) and Wellbutrin XL (GSK) affected market dynamics?
  • How is life-cycle management helping to protect revenues and extend the market?
  • To what degree will novel drugs address the unmet clinical needs of treatment-resistant depressives, estimated to be 50%-60% of the patient pool?
  • Why should Europe be of particular interest to CNS drug developers?


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options

Search Inside Report


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008